First surgical experience of intraperitoneal treatment with the trifunctional antibody catumaxomab (Anti-EpCam x Anti-CD3) for epithelial ovarian cancer

Anticancer Research

Volumn 31, Issue 8, 2011, Pages 2603-2608

  Papanikolaou, Georgios ^a   Fotopoulou, Christina ^a   Braicu, Ioana ^a   Chekerov, Radoslav ^a   Schmidt, Sven Christian ^a   Pietzner, Klaus ^a   Sehouli, Jalid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Catumaxomab; Intraperitoneal; Operative morbidity; Operative mortality; Ovarian cancer; Relapse; Surgical tumor debulking

Indexed keywords

CARBOPLATIN; CATUMAXOMAB; DOXORUBICIN; PACLITAXEL;

ABSCESS; ADULT; AGED; ANASTOMOSIS; ARTICLE; ASCITES; CANCER PATIENT; CARCINOMATOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; EPITHELIUM; EPITHELIUM TUMOR; FEMALE; HUMAN; ILEUS; INTESTINE FUNCTION; INTRAOPERATIVE PERIOD; MEDICAL DOCUMENTATION; MORBIDITY; OPERATION DURATION; OVARY CANCER; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIBODIES, BISPECIFIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFUSIONS, PARENTERAL; INTRAOPERATIVE CARE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 79961192708     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Heiss MM, Strohlein MA, Jager M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW and Lindhofer H: Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 117(3): 435-443, 2005. (Pubitemid 41429567)
2. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B and Lindhofer H: Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumour cell killing. J Immunol 163: 1246-1252, 1999. (Pubitemid 29352740)
3. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, Wollenberg B and Lindhofer H: The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83: 261-266, 2000. (Pubitemid 30411727)
4. Riesenberg R, Buchner A, Pohla H and Lindhofer H: Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (αEpCAM x αCD3). J Histochem Cytochem 49: 1-7, 2001.
5. Assessment report for Removab. International Nonproprietary Name: catumaxomab. Procedure No. EMEA/H/C/000972, Doc.Ref.: EMEA/CHMP/100434/2009, European Medicines Agency, Evaluation of Medicines for Human Use.
6. Parsons SL, Kutarska E, Koralewski P, Gore M, Wimberger P, Burges A, Stroehlein MA, Lahr A, Jaeger M and Heiss MM: Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study. J Clin Oncol 25: 5520, 2007.
7. Parsons SL, Murawa PX, Kolesnik OO, Ivanchenko VV, Koralewski P, Razbadauskas A, Stroehlein MA, Friccius-Quecke H, Jaeger M and Heiss MM: Treatment of epithelial cancer patients with malignant ascites using catumaxomab: results of the nonovarian stratum of a phase II/III study. Proc Gastrointest Cancer Symp 106, 2008.
8. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C,Lindhofer H, Lahr A and Parsons SL: The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 127(9): 2209-2221, 2010.
9. Chekerov R, Reinthaller A, Reimer D, Reimer T, Angleitner-Boubenizek L, Halfen M, Lindhofer H, Braicu I, Oskay-Özcelik G and Sehouli J: Intraoperative immunotherapy with the trifunctional antibody catumaxomab in patients with ovarian cancer: Results from a phase II study. J Clin Oncol 28(7): 5039, 2010.
10. Pietzner K, Linke RG, Jäger M, Lindhofer H, Friccius-Quecke H, Chen F, Braicu EI, Oskay-Özcelik G and Sehouli J: Phase II clinical trial to evaluate the safety of repeated cycle of intraperitoneal catumaxomab for treatment of malignant ascites (SECIMAS). J Clin Oncol, 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 28, No 15-suppl (May 20 Supplement), TPS155, 2010.
11. International Federation of Gynecology and Obstetrics. Changing in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 156: 263-264, 1987.
12. Harter P, Hahmann M, Lueck HJ, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, Hasenburg A, Burges A, Loibl S, Meier W, Huober J, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emons G and du Bois A: Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 16(5): 1324-1330, 2009.
13. Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L and Gülten OO: Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol 99(7): 424-427, 2009.
14. Sehouli J, Könsgen D, Mustea A, Oskay-Ozcelik G, Katsares I, Weidemann H and Lichtenegger W: 'IMO'- intraoperative mapping of ovarian cancer. Zentralbl Gynakol 125(3-4): 129-135, 2003.
15. Adhesion Scoring Group, Improvement of interobserver reproducibility of adhesion scoring systems, Fertil Steril 62: 984-988, 1994.
16. Cohen Z, Senagore AJ, Dayton MT, Koruda MJ, Beck DE, Wolff BG, Fleshner PR, Thirlby RC, Ludwig KA, Larach SW, Weiss EG, Bauer JJ and Holmdahl L: Prevention of postoperative abdominal adhesions by a novel, glycerol/sodium hyaluronate/ carboxymethylcellulose-based bioresorbable membrane: a prospective, randomized, evaluator-blinded multicenter study. Dis Colon Rectum 48: 1130-1139, 2005. (Pubitemid 40897855)
17. Woopen H and Sehouli J: Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res. 29(8): 3353-3359, 2009.
18. Makey JR and Venner P: Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol 6(2): 474-480, 1996.
19. Wimberger P, Heubner M and Kimmig R: Catumaxomab in the Treatment of Malignant Ascites: the Evidence of its Therapeutic Value. Clin Med Insights Ther 2: 481-489, 2010.
20. Sookhai S, Wang J, Austin K, Maguire D, Blankson S, Kirwan WO and Redmond HP: Antivascular endothelial growth factor therapy prevents peritoneal adhesion formation without adversely affecting wound strength or anastomotic integrity, British Journal of Surgery 87(7): 950-951, 2000.
21. Ignjatovic D, Aasland K, Pettersen M, Sund S, Chen Y, Spasojevic M and Nesgaard JM: Intra-abdominal administration of bevacizumab diminishes intra-peritoneal adhesions. Am J Surg 200(2): 270-275, 2010.
22. Sfakianos GP, Numnum TM, Halverson CB, Panjeti D, Kendrick JE 4th and Straughn JM Jr.: The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study. Gynecol Oncol 114(3): 424-426, 2009.
23. Scappaticci FA Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S and Hurwitz H: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91(3): 173-180, 2005. (Pubitemid 41254420)
24. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004. (Pubitemid 38702844)
25. Kozloff M, Cohn A, Christiansen N, Flynn P, Kabbinavar F, Robles R and Ulcickas-Yood M: Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): preliminary results from a larger registry in the U.S, J Clin Oncol 23: 3566, 2005.
26. Skillings JR, Johnson DH, Miller K, Kabbinavar E, Bergsland E, Holmgren SN, Holden SN, Hurwitz H and Scappaticci F: Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy, J Clin Oncol 23: 3019, 2005.
27. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004. (Pubitemid 38944402)
28. Krueger CM, Berdov BA, Roman LA, Luft AV, Lampe P, Lindhofer H, Bartelheim K, Klein A and Heiss MM: Intraoperative, adjuvant treatment of gastric cancer with the trifunctional antibody catumaxomab compared to surgery alone: A phase II study J Clin Oncol 26(755): 15529, 2008.